a Cancer Center, Union Hospital , Tongji Medical College, Huazhong University of Science and Technology , Wuhan , China.
b Department of Oncology , First Affiliated Hospital of Yangtz University , Jingzhou , China.
Cancer Biol Ther. 2018;19(12):1088-1092. doi: 10.1080/15384047.2018.1491500. Epub 2018 Aug 15.
Ovarian cancer is a most common lethal gynecological malignant tumor, with a gradual increasing incidence throughout the world. The mainstay treatment is cytoreductive surgery followed by platinum-based chemotherapy. However, a high percentage of patients recur, thus needing multiple treatments with a frequently poor prognosis. Apatinib is a novel and highly selective tyrosine kinase inhibitor of vascular endothelial growth factor receptor-2. Previous studies have suggested that apatinib is safe and effective in some solid tumors. We report one case with platinum-resistant advanced epithelial ovarian cancer, who had failed prior treatment with multiple chemotherapy reagents. She was negative for multiple driver genes including BRCA1/2、EGFR、KRAS/NRAS/BRAF, ALK, HER2 and cMET. Five courses of apatinib plus epirubicin were given. Due to the heavy leukothrombopenia, apatinib monotherapy, at 250 mg qd dose level, was used for maintenance therapy. The progression-free survival (PFS) time was 12.6 months. After that, the disease was slightly progressive during apatinib maintenance and then entered into a "stable" state until now. It indicated that apatinib may be a superior choice for advanced ovarian cancer patients, but further prospective studies are needed to optimize the treatment.
卵巢癌是最常见的致命妇科恶性肿瘤，其发病率在全球范围内逐渐上升。主要的治疗方法是细胞减灭术，然后是铂类为基础的化疗。然而，很大比例的患者会复发，因此需要多次治疗，预后通常较差。阿帕替尼是一种新型、高度选择性的血管内皮生长因子受体-2酪氨酸激酶抑制剂。先前的研究表明，阿帕替尼在一些实体肿瘤中是安全有效的。我们报告了一例铂类耐药的晚期上皮性卵巢癌患者，她对包括 BRCA1/2、EGFR、KRAS/NRAS/BRAF、ALK、HER2 和 cMET 在内的多个驱动基因检测均为阴性。她接受了 5 个疗程的阿帕替尼联合表柔比星治疗。由于严重的白细胞减少和血小板减少，阿帕替尼单药治疗（250mg qd 剂量水平）用于维持治疗。无进展生存期（PFS）为 12.6 个月。此后，在阿帕替尼维持治疗期间疾病略有进展，然后进入“稳定”状态，直到现在。这表明阿帕替尼可能是晚期卵巢癌患者的更佳选择，但需要进一步的前瞻性研究来优化治疗。
